Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

NCT05827146 is registered in ClinicalTrials.gov with Shanghai HEP Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05827146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Lead sponsor
Shanghai HEP Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2023
Completion date
February 1, 2024
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d infection